Drug Trial Radar · NCT05640245
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Dec 13, 2022
Primary completion
Sep 5, 2023
Study completion Jan 15, 2024
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Dec 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with active psoriatic arthritis. The study includes adalimumab treatment as an active reference arm.
Conditions
- Arthritis, Psoriatic
Interventions
SonelokimabDrug
randomized treatment; parallel group
PlaceboDrug
randomized treatment; parallel-group
AdalimumabDrug
randomized treatment; parallel-group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12Time frame: At Week 12
Locations
42 sites in 8 countries. Site status is shown where the registry gives one.
Clinical Site
Rancho Mirage, California
Clinical Site
Duncansville, Pennsylvania
Clinical Site
Pleven, Bulgaria
Clinical Site
Pleven, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Plovdiv, Bulgaria
Clinical Site
Rousse, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Stara Zagora, Bulgaria
Clinical Site
Varna, Bulgaria
Clinical Site
Ostrava, Czechia
Clinical Site
Tallinn, Estonia
Clinical Site
Tartu, Estonia
Clinical Site
Hamburg, Germany
Clinical Site
Herne, Germany
Clinical Site
Budapest, Hungary
Clinical Site
Budapest, Hungary
Clinical Site
Budapest, Hungary
Clinical Site
Székesfehérvár, Hungary
Clinical Site
Szentes, Hungary
Clinical Site
Veszprém, Hungary
Clinical Site
Bialystok, Poland
Clinical Site
Bialystok, Poland
Clinical Site
Bialystok, Poland
Clinical Site
Bydgoszcz, Poland
Clinical Site
Bydgoszcz, Poland
Clinical Site
Elblag, Poland
Clinical Site
Gdynia, Poland
Clinical Site
Krakow, Poland
Clinical Site
Lodz, Poland
Clinical Site
Nadarzyn, Poland
Clinical Site
Nowa Sól, Poland
Clinical Site
Olsztyn, Poland
Clinical Site
Poznan, Poland
Clinical Site
Sochaczew, Poland
Clinical Site
Swidnica, Poland
Clinical Site
Warsaw, Poland
Clinical SIte
Wroclaw, Poland
Clinical Site
Madrid, Spain
Clinical Site
Sabadell, Spain
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.